Cancer Therapy News and Research

RSS

SBIR grant from NIH to GenVec for metastatic cancer research

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.

30 Sep 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and has the largest and most versatile hyperthermia program on the West Coast, and its world-renowned Radiation Oncology team has added the capabilities of the BSD-500 to its growing hyperthermia cancer treatment program.

29 Sep 2009

CEO Cancer Gold Standard accreditation for State Farm

State Farm has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

29 Sep 2009

NovoCure initiates newly-diagnosed GBM clinical trial

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.

29 Sep 2009

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. New University of Pennsylvania School of Medicine research, however, has uncovered patterns that may help clinicians identify and help women at risk of these symptoms sooner in order to increase their chances of sticking with their treatment regimen.

29 Sep 2009

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

UCLA scientists have identified two chemicals that convince cells to ignore premature signals to stop producing important proteins. Published in the Sept. 28 edition of the Journal of Experimental Medicine, the findings could lead to new medications for genetic diseases, such as cancer and muscular dystrophy, that are sparked by missing proteins.

29 Sep 2009

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

A 220-ton cyclotron, the core of what will soon be Illinois’ most advanced radiation treatment center, has ended a 5,000-mile journey that began in Belgium, arriving at the construction site of the CDH Proton Therapy Center, a ProCure Center, located in suburban Warrenville. Capable of accelerating protons, the cyclotron is the core piece of equipment used in proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

Research study supports reovirus and cisplatin combination for cancer treatment

Oncolytics Biotech Inc. ('Oncolytics') reported today that research led by Prof. Hardev Pandha of the Royal Surrey County Hospital, U.K., was published September 22, 2009 in the online version of Clinical Cancer Research.

25 Sep 2009

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.

24 Sep 2009

Study compares benefits of laparoscopic and traditional open surgery for prostate cancer

The more things change, the more they stay the same, as the proverb goes. A study appearing in an upcoming edition of The Journal of Oncology appears to prove just that. The study compares the benefits of laparoscopic surgery versus traditional open surgery in the treatment of prostate cancer. With traditional surgery, surgeons remove the prostate gland via an incision below the belly button.

24 Sep 2009

"Top Docs" ad campaign suit resolved

Virtua may continue advertising that it has the most Top Docs as a result of a Consent Order agreed to by the parties in the suit brought by Cooper against Virtua in February 2009.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

New method found for the treatment of pancreatic cancer

For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

24 Sep 2009

Titanium dioxide nanoparticles catalyze brain tumor death

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago Medical Center's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to antibodies.

23 Sep 2009

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High Intensity Focused Ultrasound) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Niti Surgical Solutions receives patent certificates for Hand CAC 30 and CAR 31 in Japan and China

NiTi Surgical Solutions, an innovative surgical device company, today announced the Japan Patent Office and the Patent Office of China have issued patent certificates that cover two of the company’s products, the Hand CAC™ 30 Compressions Anastomosis Clip applicator and CAR™ 31 Compression Anastomosis Ring.

23 Sep 2009

Research reveals balancing act between sugar-coated nanoparticles

A research team at the National Institute of Standards and Technology (NIST) studying sugar-coated nanoparticles for use as a possible cancer therapy has uncovered a delicate balancing act that makes the particles more effective than conventional thinking says they should be. Just like individuals in a crowd respecting other people's personal space, the particles work because they get close together, but not too close.

23 Sep 2009

Cancer Therapy News and Research

SBIR grant from NIH to GenVec for metastatic cancer research

New center for gastrointestinal cancer research established

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

CEO Cancer Gold Standard accreditation for State Farm

NovoCure initiates newly-diagnosed GBM clinical trial

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Research study supports reovirus and cisplatin combination for cancer treatment

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Study compares benefits of laparoscopic and traditional open surgery for prostate cancer

"Top Docs" ad campaign suit resolved

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

New method found for the treatment of pancreatic cancer

Titanium dioxide nanoparticles catalyze brain tumor death

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

New drug test promises to yield quick and effective response for cancer therapy

Niti Surgical Solutions receives patent certificates for Hand CAC 30 and CAR 31 in Japan and China

Research reveals balancing act between sugar-coated nanoparticles

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News